Evidence map›Paper›PMID 39452947›Full record

ArticleMetabolites2024

Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto's Thyroiditis on Levothyroxine Substitution.

Eszter Berta, Sándor Halmi, István Molnár, Dávid Hutkai, Sára Csiha, Harjit Pal Bhattoa, Hajnalka Lőrincz, Sándor Somodi, Mónika Katkó, Mariann Harangi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eszter BertaDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0003-0439-9867
Sándor HalmiDoctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
István MolnárDoctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
Dávid HutkaiDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Sára CsihaDepartment of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary.
Harjit Pal BhattoaDepartment of Laboratory Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0002-4909-0065
Hajnalka LőrinczDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0009-0000-5303-3082
Sándor SomodiDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Mónika KatkóDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0002-9791-9288
Mariann HarangiDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0001-9761-9595
György ParaghDivision of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
Endre V NagyDivision of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.ORCID 0000-0002-9286-6471
Miklós BodorDepartment of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary.

Funding

National Research, Development and Innovation Office-NKFIH K142273 project
6 · The paper itself

Abstract

BACKGROUND/

objectivesFibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT).

methodsEighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay.

resultsMedian serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL;

conclusionsOur results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.

Indexed as

FGF21fibroblast growth factor 21Hashimoto’s thyroiditishyperlipidemiahypothyroidismlevothyroxinethyroid

Identifiers

PMID39452947
PMCPMC11509456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.